W
Wenming Xiao
Researcher at Center for Devices and Radiological Health
Publications - 57
Citations - 11873
Wenming Xiao is an academic researcher from Center for Devices and Radiological Health. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Gene. The author has an hindex of 26, co-authored 51 publications receiving 10031 citations. Previous affiliations of Wenming Xiao include Food and Drug Administration & Center for Information Technology.
Papers
More filters
Journal ArticleDOI
Stromal gene signatures in large-B-cell lymphomas
Georg Lenz,George E. Wright,Sandeep S. Dave,Wenming Xiao,Jonathan D. Powell,Hong Zhao,Weihong Xu,Bruce K. Tan,Neta Goldschmidt,Javeed Iqbal,Julie M. Vose,Martin Bast,Kai Fu,Dennis D. Weisenburger,Timothy C. Greiner,James O. Armitage,Alastair H. Kyle,Lorraine May,Randy D. Gascoyne,Joseph M. Connors,Gunhild Trøen,Harald Holte,Stein Kvaløy,Daan Dierickx,Gregor Verhoef,Jan Delabie,Erlend B. Smeland,Pedro Jares,A. Martinez,Armando López-Guillermo,Emili Montserrat,Elias Campo,Rita M. Braziel,Thomas P. Miller,Lisa M. Rimsza,James R. Cook,Brad Pohlman,John Sweetenham,Raymond R. Tubbs,Richard I. Fisher,Elena Hartmann,Andreas Rosenwald,German Ott,German Ott,H-K Muller-Hermelink,D Wrench,T. A. Lister,Elaine S. Jaffe,Wyndham H. Wilson,Wing C. Chan,Louis M. Staudt +50 more
TL;DR: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP.
Journal ArticleDOI
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis,Vu N. Ngo,Georg Lenz,Pavel Tolar,Ryan M. Young,Paul B. Romesser,Holger Kohlhammer,Laurence Lamy,Hong Zhao,Yandan Yang,Weihong Xu,Arthur L. Shaffer,George E. Wright,Wenming Xiao,John Powell,Jian Kang Jiang,Craig J. Thomas,Andreas Rosenwald,German Ott,Hans K. Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Nathalie A. Johnson,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Wyndham H. Wilson,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Dennis D. Weisenburger,Wing C. Chan,Susan K. Pierce,Louis M. Staudt +36 more
TL;DR: Findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
Journal ArticleDOI
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo,Vu N. Ngo,Ryan M. Young,Roland Schmitz,Sameer Jhavar,Wenming Xiao,Kian-Huat Lim,Holger Kohlhammer,Weihong Xu,Yandan Yang,Hong Zhao,Arthur L. Shaffer,Paul B. Romesser,George E. Wright,John Powell,Andreas Rosenwald,Hans K. Müller-Hermelink,German Ott,Randy D. Gascoyne,Joseph M. Connors,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Denny D. Weisenburger,Wing C. Chan,Louis M. Staudt +31 more
TL;DR: The dependence of ABC DLBCLs on MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signalling, is described and the development of inhibitors of IRAK4 kinase and other components of this pathway for the treatment of tumours bearing oncogenic MyD88 mutations are supported.
Journal ArticleDOI
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Roland Schmitz,George E. Wright,Da-Wei Huang,Calvin A. Johnson,James D. Phelan,James Q. Wang,Sandrine Roulland,Monica Kasbekar,Ryan M. Young,Arthur L. Shaffer,Daniel J. Hodson,Wenming Xiao,Xin Yu,Yandan Yang,Hong Zhao,Weihong Xu,Xuelu Liu,Bin Zhou,Wei Du,Wing C. Chan,Elaine S. Jaffe,Randy D. Gascoyne,Joseph M. Connors,Elias Campo,Armando López-Guillermo,Andreas Rosenwald,German Ott,Jan Delabie,Lisa M. Rimsza,Kevin Tay Kuang Wei,Andrew D. Zelenetz,Andrew D. Zelenetz,John P. Leonard,John P. Leonard,Nancy L. Bartlett,Nancy L. Bartlett,Bao Tran,Jyoti Shetty,Yongmei Zhao,Dan R. Soppet,Stefania Pittaluga,Wyndham H. Wilson,Louis M. Staudt +42 more
TL;DR: Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on “chronic active” B‐cell receptor signaling that is amenable to therapeutic inhibition, and an algorithm was developed and implemented to discover genetic subtypes based on the co‐occurrence of genetic alterations.
Journal ArticleDOI
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
Christina M. Annunziata,R. Eric Davis,Yulia N. Demchenko,William T. Bellamy,Ana Gabrea,Fenghuang Zhan,Georg Lenz,Ichiro Hanamura,George E. Wright,Wenming Xiao,Sandeep S. Dave,Elaine M. Hurt,Bruce K. Tan,Hong Zhao,Owen W. Stephens,Madhumita Santra,David R. Williams,Lenny Dang,Bart Barlogie,John D. Shaughnessy,W. Michael Kuehl,Louis M. Staudt +21 more
TL;DR: It is demonstrated that addiction to the NF-kappaB pathway is frequent in myeloma and suggest that IKKbeta inhibitors hold promise for the treatment of this disease.